Founded in 2004 and based in Oxford, UK and Toronto, Canada, the SGC is a non-profit public-private research partnership that drives the discovery of new medicines via scientific research, most notably solving the structures of proteins of biomedical importance (human and pathogen) to facilitate drug development. Open-access publishing of research makes new findings freely available to the whole scientific community.
Companies Eli Lilly Canada and Pfizer join previous consortium funders (the Canadian Institutes for Health Research, GlaxoSmithKline, the Novartis Research Foundation, the Ontario Ministry of Research and Innovation, and the Wellcome Trust) in a joint commitment of £31 million funds and resources worth a further £6 million over the next four years. This will fund research including a new programme on proteins involved in epigenetic mechanisms of disease.
Comment: The SGC has made a substantial contribution to biomedical knowledge already, releasing the structures of over 1200 proteins. This new phase of the project will be of broad interest for both basic and applied biomedical research and development efforts.